Chavant Capital Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination in the advanced manufacturing and advanced materials technology sectors. The company was incorporated in 2021 and is based in New York, New York.
IPO Year: 2021
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
An international expert in the financing and growth of high tech businesses LinKinVax, a clinical-stage biotechnology company specializing in the treatment of infectious diseases and certain forms of cancer, announces the appointment of Dr. Jiong Ma as independent board member. "As we enter the clinical stages of a number of drug candidates (HPV, Covid) resulting from our innovative vaccine platform, I am delighted to welcome Dr. Jiong Ma as an addition to our board. With a longstanding focus on the financing and growth of high tech businesses, her role will be to support us in our platform development strategy and to help us achieve our ambitions on a global scale. Dr. Jiong Ma benefits
IRVINE, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. ("Mobix Labs" or the "Company"), a fabless semiconductor company developing disruptive next-generation connectivity technologies for 5G infrastructure, satellite communications and defense industries, today announced that its previously announced business combination with Chavant Capital Acquisition Corp. ("Chavant") (NASDAQ:CLAY) has closed, resulting in Mobix Labs becoming a publicly traded company. The business combination and all other proposals presented were approved at an extraordinary general meeting of Chavant shareholders held on December 18, 2023. In connection with the completion of the business combination,
IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. ("Mobix Labs" or the "Company"), a fabless semiconductor company developing disruptive next-generation connectivity technologies for 5G infrastructure, satellite communications and defense industries, and Chavant Capital Acquisition Corp. (NASDAQ:CLAY) ("Chavant"), a publicly traded special purpose acquisition company, today announced that the U.S. Securities and Exchange Commission (the "SEC") has declared effective the Registration Statement on Form S-4 (as amended, the "Registration Statement") filed by Chavant and relating to the previously announced proposed business combination between Mobix Labs and Chavant (the "Bus
IRVINE, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. ("Mobix Labs" or the "Company"), an innovative provider of next generation wireless mmWave 5G and connectivity solutions, and Chavant Capital Acquisition Corp. (NASDAQ:CLAY) ("Chavant"), a publicly-traded special purpose acquisition company, announced today the filing by Chavant with the U.S. Securities and Exchange Commission ("SEC") of a registration statement on Form S-4 (the "Registration Statement") on April 7, 2023, relating to the previously announced proposed business combination of Chavant and Mobix Labs. The Registration Statement contains a preliminary proxy statement/prospectus in connection with the previousl
James Peterson, former Chairman, CEO and President of Microsemi Corporation, to serve as Executive Chairman of the Board of the combined company, Mobix Labs, Inc. ("Mobix Labs"); leading a team experienced in growing technology companies organically and accelerating growth with M&A Mobix Labs equity holders will roll 100% of their existing equity holdings into the combined company Transaction values combined company at an implied pro forma enterprise value of approximately $276 million and an implied pro forma equity value of approximately $295 million Transaction includes $30 million fully committed common stock PIPE at $10.00 per share In addition, Mobix Labs has signed a non-binding t
An international expert in the financing and growth of high tech businesses LinKinVax, a clinical-stage biotechnology company specializing in the treatment of infectious diseases and certain forms of cancer, announces the appointment of Dr. Jiong Ma as independent board member. "As we enter the clinical stages of a number of drug candidates (HPV, Covid) resulting from our innovative vaccine platform, I am delighted to welcome Dr. Jiong Ma as an addition to our board. With a longstanding focus on the financing and growth of high tech businesses, her role will be to support us in our platform development strategy and to help us achieve our ambitions on a global scale. Dr. Jiong Ma benefits
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
4 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
3 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
3 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
3 - Chavant Capital Acquisition Corp. (0001855467) (Issuer)
NT 10-Q - MOBIX LABS, INC (0001855467) (Filer)
424B3 - MOBIX LABS, INC (0001855467) (Filer)
8-K - MOBIX LABS, INC (0001855467) (Filer)
8-K - Chavant Capital Acquisition Corp. (0001855467) (Filer)
8-K - Chavant Capital Acquisition Corp. (0001855467) (Filer)
25-NSE - Chavant Capital Acquisition Corp. (0001855467) (Subject)
425 - Chavant Capital Acquisition Corp. (0001855467) (Subject)
8-K - Chavant Capital Acquisition Corp. (0001855467) (Filer)
425 - Chavant Capital Acquisition Corp. (0001855467) (Subject)
8-K - Chavant Capital Acquisition Corp. (0001855467) (Filer)
SC 13G/A - MOBIX LABS, INC (0001855467) (Subject)
SC 13D - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13D - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G/A - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G/A - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G/A - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G/A - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G - Chavant Capital Acquisition Corp. (0001855467) (Subject)
SC 13G - Chavant Capital Acquisition Corp. (0001855467) (Subject)